ZOLINZA

Zolinza Adverse Events Reported to the FDA Over Time

How are Zolinza adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Zolinza, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Zolinza is flagged as the suspect drug causing the adverse event.

Most Common Zolinza Adverse Events Reported to the FDA

What are the most common Zolinza adverse events reported to the FDA?

Nausea	55 (3.07%)
Dehydration	50 (2.79%)
Diarrhoea	43 (2.4%)
Fatigue	38 (2.12%)
Death	34 (1.9%)
Weight Decreased	34 (1.9%)
Mycosis Fungoides	32 (1.78%)
Vomiting	30 (1.67%)
Anaemia	27 (1.51%)
Pyrexia	27 (1.51%)
Thrombocytopenia	27 (1.51%)
	Show More
Decreased Appetite	26 (1.45%)
Anorexia	22 (1.23%)
Platelet Count Decreased	22 (1.23%)
Underdose	21 (1.17%)
Dizziness	20 (1.12%)
Pneumonia	20 (1.12%)
Asthenia	19 (1.06%)
Syncope	18 (1%)
Alanine Aminotransferase Increased	17 (.95%)
Myocardial Infarction	17 (.95%)
Renal Failure	17 (.95%)
Abdominal Pain	16 (.89%)
Deep Vein Thrombosis	14 (.78%)
Dysgeusia	14 (.78%)
Malaise	14 (.78%)
Respiratory Failure	14 (.78%)
Blood Creatinine Increased	13 (.73%)
Constipation	13 (.73%)
Disease Progression	13 (.73%)
Drug Ineffective	13 (.73%)
Febrile Neutropenia	13 (.73%)
White Blood Cell Count Decreased	13 (.73%)
Aspartate Aminotransferase Increase...	12 (.67%)
Sepsis	12 (.67%)
Dyspnoea	11 (.61%)
Neutropenia	11 (.61%)
Pneumonitis	11 (.61%)
Haemoglobin Decreased	10 (.56%)
Hyponatraemia	10 (.56%)
Mucosal Inflammation	10 (.56%)
Off Label Use	10 (.56%)
Pulmonary Embolism	10 (.56%)
Adverse Event	9 (.5%)
Blindness Unilateral	9 (.5%)
Cardiac Failure	9 (.5%)
General Physical Health Deteriorati...	9 (.5%)
Headache	9 (.5%)
Mass	9 (.5%)
Pleural Effusion	9 (.5%)
Rash	9 (.5%)
Renal Disorder	9 (.5%)
Renal Failure Acute	9 (.5%)
Vitreous Haemorrhage	9 (.5%)
Cardiac Failure Congestive	8 (.45%)
Hypercalcaemia	8 (.45%)
Hypokalaemia	8 (.45%)
Alopecia	7 (.39%)
Back Pain	7 (.39%)
Blood Bilirubin Increased	7 (.39%)
Chills	7 (.39%)
Dry Mouth	7 (.39%)
Hypocalcaemia	7 (.39%)
Hypotension	7 (.39%)
Oedema Peripheral	7 (.39%)
Pancytopenia	7 (.39%)
Acute Prerenal Failure	6 (.33%)
Acute Pulmonary Oedema	6 (.33%)
Aphagia	6 (.33%)
Blood Alkaline Phosphatase Increase...	6 (.33%)
Cellulitis	6 (.33%)
Drug Interaction	6 (.33%)
Drug Level Increased	6 (.33%)
Malnutrition	6 (.33%)
Muscle Spasms	6 (.33%)
Pain	6 (.33%)
Pruritus	6 (.33%)
T-cell Lymphoma	6 (.33%)
Visual Impairment	6 (.33%)
Blood Pressure Decreased	5 (.28%)
Cardio-respiratory Arrest	5 (.28%)
Condition Aggravated	5 (.28%)
Cough	5 (.28%)
Hypermagnesaemia	5 (.28%)
Hypovolaemic Shock	5 (.28%)
Infection	5 (.28%)
Injection Site Reaction	5 (.28%)
Intentional Drug Misuse	5 (.28%)
Intra-abdominal Haemorrhage	5 (.28%)
Malignant Melanoma	5 (.28%)
Pneumothorax	5 (.28%)
Small Intestinal Obstruction	5 (.28%)
Staphylococcal Infection	5 (.28%)
Supraventricular Tachycardia	5 (.28%)
Transient Ischaemic Attack	5 (.28%)
Tumour Lysis Syndrome	5 (.28%)
White Blood Cell Count Increased	5 (.28%)
Abdominal Pain Lower	4 (.22%)
Acute Myeloid Leukaemia	4 (.22%)
Adverse Drug Reaction	4 (.22%)
Arrhythmia	4 (.22%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Zolinza, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Zolinza is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Zolinza

What are the most common Zolinza adverse events reported to the FDA?

Gastrointestinal Signs	126 (7.03%)
Electrolyte And Fluid Balance Condi...	78 (4.35%)
Neurological	78 (4.35%)
Hematology Investigations	70 (3.9%)
Appetite And General Nutritional	61 (3.4%)
Gastrointestinal Motility And Defec...	59 (3.29%)
Infections - Pathogen Unspecified	53 (2.96%)
Hepatobiliary	49 (2.73%)
Respiratory	46 (2.57%)
Lymphomas Non-hodgkins T-cell	43 (2.4%)
Renal Disorders	43 (2.4%)
	Show More
Anemias Nonhemolytic And Marrow Dep...	42 (2.34%)
Epidermal And Dermal Conditions	39 (2.18%)
Fatal Outcomes	38 (2.12%)
Physical Examination Topics	35 (1.95%)
Therapeutic And Nontherapeutic Effe...	34 (1.9%)
Platelet	32 (1.78%)
White Blood Cell	30 (1.67%)
Body Temperature Conditions	28 (1.56%)
Bone, Calcium, Magnesium And Phosph...	26 (1.45%)
Lower Respiratory Tract Disorders	26 (1.45%)
Cardiac Arrhythmias	25 (1.39%)
Medication Errors	23 (1.28%)
Renal And Urinary Tract Investigati...	22 (1.23%)
Bacterial Infectious	19 (1.06%)
Coronary Artery	17 (.95%)
Embolism And Thrombosis	17 (.95%)
Heart Failures	17 (.95%)
Cardiac And Vascular Investigations	15 (.84%)
Pleural	15 (.84%)
Vision	15 (.84%)
Microbiology And Serology	14 (.78%)
Skin Appendage Conditions	14 (.78%)
Decreased And Nonspecific Blood Pre...	13 (.73%)
Tissue	13 (.73%)
Gastrointestinal Vascular Condition...	12 (.67%)
Enzyme	11 (.61%)
Injuries	11 (.61%)
Pulmonary Vascular	11 (.61%)
Central Nervous System Vascular	10 (.56%)
Fungal Infectious	10 (.56%)
Muscle	10 (.56%)
Musculoskeletal And Connective Tiss...	10 (.56%)
Therapeutic Procedures And Supporti...	10 (.56%)
Gastrointestinal Hemorrhages	9 (.5%)
Gastrointestinal Stenosis And Obstr...	9 (.5%)
Headaches	9 (.5%)
Retina, Choroid And Vitreous Hemorr...	9 (.5%)
Water, Electrolyte And Mineral	9 (.5%)
Metabolic, Nutritional And Blood Ga...	8 (.45%)
Salivary Gland Conditions	8 (.45%)
Glucose Metabolism Disorders	7 (.39%)
Urinary Tract Signs	7 (.39%)
Administration Site Reactions	6 (.33%)
Hemolyses And Related Conditions	6 (.33%)
Leukemias	6 (.33%)
Protein And Chemistry Analyses	6 (.33%)
Skin And Subcutaneous Tissue	6 (.33%)
Toxicology And Therapeutic Drug Mon...	6 (.33%)
Miscellaneous And Site Unspecified ...	5 (.28%)
Neoplasm Related Morbidities	5 (.28%)
Psychiatric	5 (.28%)
Skin Neoplasms Malignant And Unspec...	5 (.28%)
Acid-base	4 (.22%)
Deliria	4 (.22%)
Disturbances In Thinking	4 (.22%)
Gastrointestinal Ulceration And Per...	4 (.22%)
Hearing	4 (.22%)
Hepatic And Hepatobiliary	4 (.22%)
Peripheral Neuropathies	4 (.22%)
Plasma Cell Neoplasms	4 (.22%)
Sleep Disorders	4 (.22%)
Spleen, Lymphatic And Reticulendoth...	4 (.22%)
Upper Respiratory Tract Disorders	4 (.22%)
Vascular Hemorrhagic	4 (.22%)
Cardiac Disorder Signs	3 (.17%)
Diabetic Complications	3 (.17%)
Gastrointestinal Inflammatory Condi...	3 (.17%)
Metastases	3 (.17%)
Ocular Infections, Irritations And ...	3 (.17%)
Peritoneal And Retroperitoneal Cond...	3 (.17%)
Procedural And Device Related Injur...	3 (.17%)
Tongue Conditions	3 (.17%)
Viral Infectious	3 (.17%)
Allergic Conditions	2 (.11%)
Anxiety Disorders	2 (.11%)
Arteriosclerosis, Stenosis, Vascula...	2 (.11%)
Bone And Joint Injuries	2 (.11%)
Bone Disorders	2 (.11%)
Bronchial Disorders	2 (.11%)
Changes In Physical Activity	2 (.11%)
Chemical Injury And Poisoning	2 (.11%)
Cornification And Dystrophic Skin	2 (.11%)
Eating Disorders	2 (.11%)
Endocrine Investigations	2 (.11%)
Exocrine Pancreas Conditions	2 (.11%)
Eye	2 (.11%)
Hematological And Lymphoid Tissue T...	2 (.11%)
Immune	2 (.11%)
Investigations, Imaging And Histopa...	2 (.11%)
Mood Disorders	2 (.11%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Zolinza, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Zolinza is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.